☰

Masaru Yamamoto - Publications

Affiliations: 
University of Nebraska Medical Center, Omaha, NE, United States 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Yamamoto M, Ikezu T. CCR2 chemokine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-7. DOI: 10.1016/B978-008055232-3.60187-4  0.479
2011 Yamamoto M, Ikezu T. CCR1 chemokine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-10. DOI: 10.1016/B978-008055232-3.60185-0  0.485
2009 Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 803-809. PMID 28189021 DOI: 10.1038/mt.2009.44  0.777
2009 Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. Plos One. 4: e6197. PMID 19593388 DOI: 10.1371/Journal.Pone.0006197  0.806
2009 Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 803-9. PMID 19277012 DOI: 10.1038/Mt.2009.44  0.799
2008 Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. Journal of Immunology (Baltimore, Md. : 1950). 181: 3877-86. PMID 18768842 DOI: 10.4049/Jimmunol.181.6.3877  0.793
2008 Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky Y, Ikezu T. Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. The American Journal of Pathology. 172: 521-33. PMID 18187566 DOI: 10.2353/Ajpath.2008.070076  0.69
2008 Ikezu T, Kiyota T, Yamamoto M, Xu J, Jacobsen MT, Okuyama S. O1-04-08: Therapeutic application of anti-inflammatory cytokines an Abeta-induced cognitive dysfunction Alzheimer's & Dementia. 4: T116-T117. DOI: 10.1016/J.Jalz.2008.05.245  0.681
2007 Yamamoto M, Kiyota T, Walsh SM, Ikezu T. Kinetic analysis of aggregated amyloid-beta peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 2: 213-21. PMID 18040846 DOI: 10.1007/S11481-006-9049-8  0.801
2007 Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. The American Journal of Pathology. 170: 680-92. PMID 17255335 DOI: 10.2353/Ajpath.2007.060378  0.738
2005 Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. The American Journal of Pathology. 166: 1475-85. PMID 15855647 DOI: 10.1016/S0002-9440(10)62364-4  0.802
Show low-probability matches.